USP32 promotes temporomandibular joint osteoarthritis by modulating PKM2 stability and glycolytic metabolism in chondrocytes
研究发现USP32在颞下颌关节骨关节炎（TMJOA）中起关键作用，通过调节PKM2的稳定性和糖酵解代谢，促进软骨细胞的炎症和凋亡。USP32的上调与TMJOA的进展相关，抑制USP32可减轻病理变化，显示出其作为潜在治疗靶点的前景。这一发现为TMJOA的病理机制提供了新的见解，并可能推动相关治疗策略的发展。
Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var
iMQT_020 is a pioneering allosteric inhibitor targeting the mitochondrial glutamine transporter SLC1A5_var, crucial for cancer cell metabolism. This compound disrupts glutaminolysis, leading to reduced tumor growth and enhanced immune responses, particularly in pancreatic cancer. In preclinical models, iMQT_020 demonstrated significant efficacy, suggesting its potential as a novel therapeutic strategy in oncology, especially when combined with immune checkpoint inhibitors.
Orphan nuclear receptor 4A1 (NR4A1) and NR4A2 are endogenous regulators of CD71 and their ligands induce ferroptosis in breast cancer
研究发现，孤儿核受体NR4A1和NR4A2在三阴性乳腺癌细胞中调节CD71表达，并通过其配体DIM-3,5化合物诱导铁死亡。DIM-3,5化合物表现出抑制肿瘤生长的潜力，可能为三阴性乳腺癌的治疗提供新的策略。
Engineered human induced pluripotent stem cell models reveal altered podocytogenesis in congenital heart disease-associated SMAD2 mutations
该研究利用工程化的人诱导多能干细胞模型，探讨了与先天性心脏病相关的SMAD2突变对肾脏细胞命运和功能的影响。研究表明，SMAD2突变导致肾小管生成的异常，可能与多脏器功能障碍相关。通过CRISPR技术和微流控器件，研究揭示了SMAD2在肾脏发育中的关键作用，为未来的靶向再生治疗提供了新的思路。
TRIM8-dependent K63-ubiquitinated PGK1 promotes glycolysis and angiogenesis in gastric cancer via interaction with ACAT1
研究发现TRIM8通过K63泛素化PGK1，促进其稳定性，从而增强胃癌细胞的糖酵解和血管生成。TRIM8水平与胃癌患者的血管生成和预后呈正相关，揭示了其作为潜在治疗靶点的重要性。这一发现为胃癌的治疗提供了新的思路，强调了代谢与血管生成之间的联系。
Identification of SLC7A1 as a potential therapeutic target for high-grade meningioma
本研究识别了SLC7A1作为高等级脑膜瘤的潜在治疗靶点，其高表达与患者预后不良相关。通过转录组分析，发现SLC7A1调控多条与肿瘤增殖相关的信号通路。此外，AZ628被预测为针对高SLC7A1脑膜瘤的有效小分子药物，显示出良好的抗肿瘤效果。这些发现为高等级脑膜瘤的治疗提供了新的思路和潜在的药物开发方向。
Understanding the molecular basis of mesenchymal stem cell stemness: implications for clinical applications
The review discusses the molecular mechanisms that govern the stemness of human mesenchymal stem cells (MSCs), which are critical for their therapeutic applications in regenerative medicine. It highlights the role of various genetic factors and transcriptional regulators in maintaining MSC properties, emphasizing the need for a comprehensive understanding of these mechanisms to enhance clinical outcomes and develop effective MSC-based therapies.
FBXW7-mediated CHK2 regulation modulates DNA damage response and cellular stability in Huntington’s disease
研究探讨了FBXW7介导的CHK2调控在亨廷顿病中的DNA损伤反应和细胞稳定性。结果表明，FBXW7的上调导致CHK2水平降低，进而影响细胞对DNA损伤的反应。这一机制可能为亨廷顿病的治疗提供新的靶点，强调了FBXW7在神经退行性疾病中的重要性。
KDM6A phosphorylation suppresses PER2 to confer a glycolytic vulnerability in HNSCC
本研究揭示了KDM6A的Ser829位点磷酸化在头颈鳞状细胞癌（HNSCC）中的重要作用，表明其通过抑制PER2表达来促进糖酵解和肿瘤生长。研究结果显示KDM6A-pSer829在多种癌症中高表达，提示其作为潜在治疗靶点的价值。这一发现为HNSCC的治疗提供了新的思路，同时也为相关投资提供了良好的商业前景。
Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway
该研究构建了METex14Del突变在肺癌中的调控网络，揭示了RAS-ERK信号通路在细胞迁移和侵袭中的关键作用。通过转录组分析，研究发现ETS1、FOSL1和SMAD3等转录因子在HGF刺激下被激活，影响相关靶基因的表达。这一发现为肺癌的靶向治疗提供了新的思路，具有重要的商业投资潜力。
PARP1-TRPM2-PKC cascade distinctly regulates reactive astrogliosis and clasmatodendrosis through NF-κB and AKT pathways in the hippocampus of chronic epilepsy rats
研究发现，PARP1-TRPM2-PKC信号通路在慢性癫痫大鼠海马中调控反应性星形胶质细胞增生和clasmatodendrosis。TRPM2在反应性星形胶质细胞中上调，NAC和PJ34通过上调PHLPP1表达减轻clasmatodendrosis。这一发现为癫痫及其他神经退行性疾病的治疗提供了新的思路。
Atypical cadherin CELSR2 acts as a therapeutic target for glioma through WNT3A/β-catenin signaling
CELSR2 is identified as a critical regulator in glioma development, promoting tumor growth through WNT3A/β-catenin signaling. The study demonstrates that knocking down CELSR2 inhibits glioma cell proliferation and alters key signaling pathways. Additionally, the use of magnetic nanoparticles for targeted delivery of CELSR2-siRNA shows promise as a novel therapeutic strategy for glioma treatment, potentially improving patient outcomes.
Hijacking mutant p53 abundance
研究提出了一种新的‘p53条件性’接近策略，旨在靶向TP53突变驱动的癌症，利用突变p53蛋白的丰度。这一策略可能为癌症治疗提供新的方向，尤其是在面对TP53突变的异质性和功能获得性肿瘤特性时。
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
G-6599 is a newly designed monovalent degrader targeting SMARCA2/A4, demonstrating exceptional degradation potency and specificity. It operates through the ubiquitin-proteasome pathway, recruiting the E3 ligase FBXO22, which enhances its therapeutic potential in treating AR-dependent prostate cancers. The study emphasizes the innovative approach of rationally designing degraders from existing ligands, showcasing significant advancements in targeted protein degradation strategies.
Determination of key functional structures of an amorphous VHL-based SMARCA2 PROTAC
研究确定了基于VHL的SMARCA2 PROTAC的关键功能结构，揭示了其在靶向蛋白降解中的潜力。通过核磁共振（NMR）晶体学，研究者们探讨了PROTAC 2的无定形固体形式的原子级结构，强调了其在靶向难以药物化的蛋白质方面的应用价值。这项研究为未来开发更高效的降解剂提供了重要的结构基础，尤其是在肿瘤学领域。